author_facet Gilman, J K
Jalal, S
Naccarelli, G V
Gilman, J K
Jalal, S
Naccarelli, G V
author Gilman, J K
Jalal, S
Naccarelli, G V
spellingShingle Gilman, J K
Jalal, S
Naccarelli, G V
Circulation
Predicting and preventing sudden death from cardiac causes.
Physiology (medical)
Cardiology and Cardiovascular Medicine
author_sort gilman, j k
spelling Gilman, J K Jalal, S Naccarelli, G V 0009-7322 1524-4539 Ovid Technologies (Wolters Kluwer Health) Physiology (medical) Cardiology and Cardiovascular Medicine http://dx.doi.org/10.1161/01.cir.90.2.1083 <jats:p>Sudden cardiac death usually occurs secondary to a ventricular tachyarrhythmia. Even under ideal circumstances only 20% of patients who have an out-of-hospital cardiac arrest survive to hospital discharge. Therefore, aggressive treatment and screening of high-risk patients are mandatory to improve survival rates. Risk stratification of high-risk patients, such as the post-myocardial infarction (MI) population, has been of limited value. Between 70% and 85% of "high-risk" post-MI patients, as defined by these screening tests, will not have a sustained ventricular tachyarrhythmia over several years of follow-up. The use of beta-blockers and possibly amiodarone may have some benefit in reducing mortality in high-risk patients after an MI. Several ongoing trials are studying the use of serial drug testing, amiodarone, and implantable cardioverter-defibrillators in reducing the incidence of sudden cardiac death in patients with potentially lethal ventricular arrhythmias. Although implantable cardioverter-defibrillators appear to be superior to antiarrhythmic drugs in reducing sudden cardiac death, total mortality may not be altered. In sustained ventricular tachyarrhythmias, sotalol and amiodarone appear to be superior to other drugs in preventing arrhythmia recurrence. Ongoing trials, such as the Antiarrhythmic Drug versus Implantable Device (AVID) trial may define the best strategy in these high-risk patients.</jats:p> Predicting and preventing sudden death from cardiac causes. Circulation
doi_str_mv 10.1161/01.cir.90.2.1083
facet_avail Online
Free
finc_class_facet Biologie
Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE2MS8wMS5jaXIuOTAuMi4xMDgz
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE2MS8wMS5jaXIuOTAuMi4xMDgz
institution DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
imprint Ovid Technologies (Wolters Kluwer Health), 1994
imprint_str_mv Ovid Technologies (Wolters Kluwer Health), 1994
issn 0009-7322
1524-4539
issn_str_mv 0009-7322
1524-4539
language English
mega_collection Ovid Technologies (Wolters Kluwer Health) (CrossRef)
match_str gilman1994predictingandpreventingsuddendeathfromcardiaccauses
publishDateSort 1994
publisher Ovid Technologies (Wolters Kluwer Health)
recordtype ai
record_format ai
series Circulation
source_id 49
title Predicting and preventing sudden death from cardiac causes.
title_unstemmed Predicting and preventing sudden death from cardiac causes.
title_full Predicting and preventing sudden death from cardiac causes.
title_fullStr Predicting and preventing sudden death from cardiac causes.
title_full_unstemmed Predicting and preventing sudden death from cardiac causes.
title_short Predicting and preventing sudden death from cardiac causes.
title_sort predicting and preventing sudden death from cardiac causes.
topic Physiology (medical)
Cardiology and Cardiovascular Medicine
url http://dx.doi.org/10.1161/01.cir.90.2.1083
publishDate 1994
physical 1083-1092
description <jats:p>Sudden cardiac death usually occurs secondary to a ventricular tachyarrhythmia. Even under ideal circumstances only 20% of patients who have an out-of-hospital cardiac arrest survive to hospital discharge. Therefore, aggressive treatment and screening of high-risk patients are mandatory to improve survival rates. Risk stratification of high-risk patients, such as the post-myocardial infarction (MI) population, has been of limited value. Between 70% and 85% of "high-risk" post-MI patients, as defined by these screening tests, will not have a sustained ventricular tachyarrhythmia over several years of follow-up. The use of beta-blockers and possibly amiodarone may have some benefit in reducing mortality in high-risk patients after an MI. Several ongoing trials are studying the use of serial drug testing, amiodarone, and implantable cardioverter-defibrillators in reducing the incidence of sudden cardiac death in patients with potentially lethal ventricular arrhythmias. Although implantable cardioverter-defibrillators appear to be superior to antiarrhythmic drugs in reducing sudden cardiac death, total mortality may not be altered. In sustained ventricular tachyarrhythmias, sotalol and amiodarone appear to be superior to other drugs in preventing arrhythmia recurrence. Ongoing trials, such as the Antiarrhythmic Drug versus Implantable Device (AVID) trial may define the best strategy in these high-risk patients.</jats:p>
container_issue 2
container_start_page 1083
container_title Circulation
container_volume 90
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792341682157518851
geogr_code not assigned
last_indexed 2024-03-01T16:22:00.24Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Predicting+and+preventing+sudden+death+from+cardiac+causes.&rft.date=1994-08-01&genre=article&issn=1524-4539&volume=90&issue=2&spage=1083&epage=1092&pages=1083-1092&jtitle=Circulation&atitle=Predicting+and+preventing+sudden+death+from+cardiac+causes.&aulast=Naccarelli&aufirst=G+V&rft_id=info%3Adoi%2F10.1161%2F01.cir.90.2.1083&rft.language%5B0%5D=eng
SOLR
_version_ 1792341682157518851
author Gilman, J K, Jalal, S, Naccarelli, G V
author_facet Gilman, J K, Jalal, S, Naccarelli, G V, Gilman, J K, Jalal, S, Naccarelli, G V
author_sort gilman, j k
container_issue 2
container_start_page 1083
container_title Circulation
container_volume 90
description <jats:p>Sudden cardiac death usually occurs secondary to a ventricular tachyarrhythmia. Even under ideal circumstances only 20% of patients who have an out-of-hospital cardiac arrest survive to hospital discharge. Therefore, aggressive treatment and screening of high-risk patients are mandatory to improve survival rates. Risk stratification of high-risk patients, such as the post-myocardial infarction (MI) population, has been of limited value. Between 70% and 85% of "high-risk" post-MI patients, as defined by these screening tests, will not have a sustained ventricular tachyarrhythmia over several years of follow-up. The use of beta-blockers and possibly amiodarone may have some benefit in reducing mortality in high-risk patients after an MI. Several ongoing trials are studying the use of serial drug testing, amiodarone, and implantable cardioverter-defibrillators in reducing the incidence of sudden cardiac death in patients with potentially lethal ventricular arrhythmias. Although implantable cardioverter-defibrillators appear to be superior to antiarrhythmic drugs in reducing sudden cardiac death, total mortality may not be altered. In sustained ventricular tachyarrhythmias, sotalol and amiodarone appear to be superior to other drugs in preventing arrhythmia recurrence. Ongoing trials, such as the Antiarrhythmic Drug versus Implantable Device (AVID) trial may define the best strategy in these high-risk patients.</jats:p>
doi_str_mv 10.1161/01.cir.90.2.1083
facet_avail Online, Free
finc_class_facet Biologie, Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE2MS8wMS5jaXIuOTAuMi4xMDgz
imprint Ovid Technologies (Wolters Kluwer Health), 1994
imprint_str_mv Ovid Technologies (Wolters Kluwer Health), 1994
institution DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229
issn 0009-7322, 1524-4539
issn_str_mv 0009-7322, 1524-4539
language English
last_indexed 2024-03-01T16:22:00.24Z
match_str gilman1994predictingandpreventingsuddendeathfromcardiaccauses
mega_collection Ovid Technologies (Wolters Kluwer Health) (CrossRef)
physical 1083-1092
publishDate 1994
publishDateSort 1994
publisher Ovid Technologies (Wolters Kluwer Health)
record_format ai
recordtype ai
series Circulation
source_id 49
spelling Gilman, J K Jalal, S Naccarelli, G V 0009-7322 1524-4539 Ovid Technologies (Wolters Kluwer Health) Physiology (medical) Cardiology and Cardiovascular Medicine http://dx.doi.org/10.1161/01.cir.90.2.1083 <jats:p>Sudden cardiac death usually occurs secondary to a ventricular tachyarrhythmia. Even under ideal circumstances only 20% of patients who have an out-of-hospital cardiac arrest survive to hospital discharge. Therefore, aggressive treatment and screening of high-risk patients are mandatory to improve survival rates. Risk stratification of high-risk patients, such as the post-myocardial infarction (MI) population, has been of limited value. Between 70% and 85% of "high-risk" post-MI patients, as defined by these screening tests, will not have a sustained ventricular tachyarrhythmia over several years of follow-up. The use of beta-blockers and possibly amiodarone may have some benefit in reducing mortality in high-risk patients after an MI. Several ongoing trials are studying the use of serial drug testing, amiodarone, and implantable cardioverter-defibrillators in reducing the incidence of sudden cardiac death in patients with potentially lethal ventricular arrhythmias. Although implantable cardioverter-defibrillators appear to be superior to antiarrhythmic drugs in reducing sudden cardiac death, total mortality may not be altered. In sustained ventricular tachyarrhythmias, sotalol and amiodarone appear to be superior to other drugs in preventing arrhythmia recurrence. Ongoing trials, such as the Antiarrhythmic Drug versus Implantable Device (AVID) trial may define the best strategy in these high-risk patients.</jats:p> Predicting and preventing sudden death from cardiac causes. Circulation
spellingShingle Gilman, J K, Jalal, S, Naccarelli, G V, Circulation, Predicting and preventing sudden death from cardiac causes., Physiology (medical), Cardiology and Cardiovascular Medicine
title Predicting and preventing sudden death from cardiac causes.
title_full Predicting and preventing sudden death from cardiac causes.
title_fullStr Predicting and preventing sudden death from cardiac causes.
title_full_unstemmed Predicting and preventing sudden death from cardiac causes.
title_short Predicting and preventing sudden death from cardiac causes.
title_sort predicting and preventing sudden death from cardiac causes.
title_unstemmed Predicting and preventing sudden death from cardiac causes.
topic Physiology (medical), Cardiology and Cardiovascular Medicine
url http://dx.doi.org/10.1161/01.cir.90.2.1083